Infinity Pharmaceuticals Inc. (INFI) Analysts See $-0.22 EPS; Bluerock Residential Growth Reit (NYSEMKT:BRG) Shorts Lowered By 0.02%

July 26, 2017 - By Migdalia James

Bluerock Residential Growth Reit (NYSEMKT:BRG) had a decrease of 0.02% in short interest. BRG’s SI was 842,400 shares in July as released by FINRA. Its down 0.02% from 842,600 shares previously. With 131,500 avg volume, 6 days are for Bluerock Residential Growth Reit (NYSEMKT:BRG)’s short sellers to cover BRG’s short positions. The SI to Bluerock Residential Growth Reit’s float is 3.5%. About 40,316 shares traded. Bluerock Residential Growth REIT Inc (NYSEMKT:BRG) has risen 10.90% since July 26, 2016 and is uptrending. It has underperformed by 5.80% the S&P500.

Analysts expect Infinity Pharmaceuticals Inc. (NASDAQ:INFI) to report $-0.22 EPS on August, 8.They anticipate $0.21 EPS change or 48.84% from last quarter’s $-0.43 EPS. After having $-0.21 EPS previously, Infinity Pharmaceuticals Inc.’s analysts see 4.76% EPS growth. About 52,207 shares traded. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has declined 60.96% since July 26, 2016 and is downtrending. It has underperformed by 77.66% the S&P500.

Among 4 analysts covering Bluerock Residential Growth REIT (NYSEMKT:BRG), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Bluerock Residential Growth REIT had 4 analyst reports since August 20, 2015 according to SRatingsIntel. Compass Point maintained Bluerock Residential Growth REIT Inc (NYSEMKT:BRG) on Thursday, August 20 with “Buy” rating. As per Wednesday, January 4, the company rating was downgraded by FBR Capital. JMP Securities initiated the stock with “Market Outperform” rating in Thursday, July 21 report.

Bluerock Residential Growth REIT, Inc. is a real estate investment trust. The company has market cap of $325.35 million. The Firm is focused on acquiring a portfolio of residential real estate assets. It currently has negative earnings. As of December 31, 2016, the Company’s portfolio consisted of interests in 31 properties .

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $70.13 million. The Firm is engaged in the discovery, development and delivery of medicines to treat diseases. It has a 108.81 P/E ratio. The Firm develops small molecule drugs that target disease pathways for potential applications in oncology.

Investors sentiment decreased to 0.84 in 2016 Q4. Its down 0.09, from 0.93 in 2016Q3. It fall, as 16 investors sold Infinity Pharmaceuticals Inc. shares while 27 reduced holdings. 10 funds opened positions while 26 raised stakes. 38.25 million shares or 2.94% less from 39.40 million shares in 2016Q3 were reported. Bancshares Of Mellon Corp has invested 0% in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Evercore Wealth Mgmt Lc has invested 0.01% of its portfolio in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Blackrock Inv Ltd Co holds 0% of its portfolio in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) for 185,871 shares. Grp One Trading Lp holds 0% of its portfolio in Infinity Pharmaceuticals Inc. (NASDAQ:INFI) for 23,009 shares. 766,282 are owned by Northern. 91,900 were accumulated by California Employees Retirement System. Panagora Asset holds 0% or 8,057 shares in its portfolio. Moreover, Goldman Sachs Grp has 0% invested in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Amer Int Grp Incorporated invested in 28,249 shares or 0% of the stock. Federated Invsts Pa reported 3,876 shares stake. Next Finance stated it has 0% in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). 330,361 were accumulated by Geode Management Lc. The California-based Aperio Llc has invested 0% in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Price T Rowe Assocs Md has invested 0% in Infinity Pharmaceuticals Inc. (NASDAQ:INFI). Deutsche Retail Bank Ag accumulated 483,875 shares.

Among 9 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 1 have Buy rating, 0 Sell and 8 Hold. Therefore 11% are positive. Infinity Pharmaceutical had 15 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Morgan Stanley given on Monday, September 21. RBC Capital Markets maintained Infinity Pharmaceuticals Inc. (NASDAQ:INFI) rating on Friday, August 7. RBC Capital Markets has “Outperform” rating and $15 target. The firm has “Market Perform” rating by William Blair given on Wednesday, June 15. Morgan Stanley downgraded it to “Equal-Weight” rating and $1 target in Wednesday, June 15 report. On Wednesday, March 2 the stock rating was initiated by FBR Capital with “Outperform”. The stock of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) earned “Market Outperform” rating by JMP Securities on Wednesday, March 9. The firm earned “Sector Perform” rating on Wednesday, June 15 by RBC Capital Markets. The company was downgraded on Wednesday, June 15 by Jefferies. As per Tuesday, June 14, the company rating was downgraded by . JMP Securities downgraded Infinity Pharmaceuticals Inc. (NASDAQ:INFI) on Tuesday, June 14 to “Market Perform” rating.